Regenerative therapy in cardiology by human amnion-derived immunotolerant cells in allogeneic combination

• Project/Area Number: 23791861
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Obstetrics and gynecology
• Research Institution: National Research Institute for Child Health and Development
• Principal Investigator: NISHIYAMA Hiroko 独立行政法人国立成育医療研究センター, その他部局等, 研究員 (70383891)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
• Keywords: 産科学 / 羊膜 / アログラフト / 再生医療 / 羊膜細胞 / 心筋 / 間葉系細胞 / 免疫寛容

Research Abstract

At present, the definitive therapy to patients with severe heart failure is only heart transplantation. However, lack of donor organs is indeed a social problem in the world. We have previously established isolation system of mesenchymal stem cells from amnion, and showed availability of amnion-derived cells as a transplantable biomaterial. Once availability of amnion-derived cells from the viewpoint of regenerative therapy is established, cell source problem must be solved. In this study, we showed long-term survival of amnion-derived cells and elucidate mechanism of in vivo immune tolerance.